/

PostEra

  • What it is:PostEra is an AI-driven biopharma company using its Proton platform for machine learning-powered medicinal chemistry to accelerate small molecule drug discovery.
  • Best for:Large biopharma companies, Small molecule discovery teams, Pandemic preparedness programs
  • Pricing:Starting from Custom (e.g., $12M upfront + milestones + royalties)
  • Rating:88/100Very Good
  • Expert's conclusion:PostEra is best suited for pharmaceutical companies that want to accelerate medicinal chemistry through proven AI partnerships; however, the company will require an enterprise-level commitment.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is PostEra and What Does It Do?

PostEra is a biopharmaceutical company that uses artificial intelligence (AI) and machine learning (ML) to speed up medicinal chemistry and drug discovery. PostEra’s Proton AI Platform is used for optimizing small molecule drugs, and also supports internal and partner programs with leading pharmaceutical companies.

Active
📍Boston, MA
📅Founded 2019
🏢Private
TARGET SEGMENTS
Biopharma CompaniesPharmaceutical ResearchNIH and Public Sector

What Are PostEra's Key Business Metrics?

📊
$26M
Funding Raised
📊
$1Bn+
AI Partnerships Value
🏢
40
Team Size
📊
4 partnered programs
Preclinical Programs
📊
PCOS, Reproductive Endocrinology, Fertility
Internal Pipeline Areas

How Credible and Trustworthy Is PostEra?

88/100
Excellent

Credibility in AI drug discovery has been demonstrated by strong validation from collaborations totaling over $1 billion with Pfizer, Amgen, and NIH as well as significant impact of COVID Moonshot on drug discovery.

BREAKDOWN
Product Maturity85/100
Company Stability90/100
Security & Compliance75/100
User Reviews80/100
Transparency85/100
Support Quality90/100
TRUST SIGNALS
Multi-year partnerships with Pfizer and Amgen totaling $1Bn+Led COVID Moonshot - world's largest open-science drug discoveryNIH grants and collaborationsY Combinator W20 alumni

What is the history of PostEra and its key milestones?

2019

Company Founded

Founded by Aaron Morris and Alpha Lee based on research conducted at Oxford University in AI-driven medicinal chemistry.

2020

Y Combinator & US Launch

Participated in the Y Combinator Winter 2020 class and established U.S. operations in Boston.

2020

COVID Moonshot Launch

Led and executed the world’s largest open-science drug discovery effort to discover COVID antivirals.

2020

Pfizer Partnership

Initial collaboration was signed with Pfizer to utilize company data to increase efficiency in drug discovery.

2022

Series A & NIH Center

Series A funding of $24 million and opened an NIH-funded antiviral drug discovery center.

2023

Amgen Partnership

Collaboration agreement was signed with Amgen to develop up to five small-molecule programs.

2024

Pfizer ADC Expansion

Collaborative agreement with Pfizer was expanded to include up to $350 million for development of antibody-drug conjugates.

2025

Pfizer Extension

Expanded collaboration agreement with Pfizer including ADCs was added to the original agreement.

What Are the Key Features of PostEra?

📊
Proton AI Platform
End-to-end ML platform to reduce the time required for the Design-Make-Test cycle of medicinal chemistry.
✨
Structure-Enabled AI Design
Identifies high potential areas for chemical interactions with proteins and simulates the binding interactions.
✨
Non-Structural AI Tools
Generative model to predict structure for targets without a known structure using advanced predictive chemistry methods.
✨
Parallel Medicinal Chemistry
Prioritization of molecular modification options using shared synthetic intermediates and AI-driven methodology.
✨
Active Learning
New approach to collect maximal information from experimental data during each discovery cycle.
✨
Synthesis Route Prediction
Best-in-class models ensure reliable synthetic pathways for all designed molecules.
✨
Target Product Profile Alignment
Candidates are optimized against pre-defined TPP criteria continuously throughout the entire discovery process.

What Technology Stack and Infrastructure Does PostEra Use?

Infrastructure

Cloud-based with parallel synthesis capabilities

Technologies

Machine LearningDeep LearningActive LearningComputational Chemistry

Integrations

Pharma Assay CascadesMedicinal Chemistry WorkflowsHigh-Throughput Synthesis

AI/ML Capabilities

Proprietary Proton platform featuring structure-enabled and non-structural AI for molecule design, synthesis route prediction, active learning from experiments, and parallel medicinal chemistry optimization

Based on official website technical descriptions and peer-reviewed methodology publications

What Are the Best Use Cases for PostEra?

Large Pharma Medicinal Chemists
Speed up your hit-to-lead optimizations to as much as three to five times faster using AI molecule design for synthesis planning and experimental priority
Biotech Drug Discovery Teams
Use an enterprise-grade AI chemistry platform with our co-discovery partners without building your own machine learning infrastructure
Academic Research Groups
Utilize proven AI tools from open science collaborations such as COVID Moonshot for the exploration of new targets
NOT FORBiologics/Protein Therapeutics Teams
The focus is on small molecule chemistry - therefore this will have limited application for antibody, ADC, or biologics discovery
NOT FORNon-Pharma Enterprises
These are specialized for medicinal chemistry use cases and not for general corporate AI automation needs

How Much Does PostEra Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Biopharma PartnershipsCustom (e.g., $12M upfront + milestones + royalties)Multi-year collaborations for AI-driven drug discovery programsPfizer collaboration announcement
NIH Grant Funding$68MFunding for AI-powered antiviral drug discovery consortiumNIH partnership announcement
Internal Pipeline DevelopmentN/A - Wholly owned programsPCOS, reproductive endocrinology, fertility programs—
Biopharma PartnershipsCustom (e.g., $12M upfront + milestones + royalties)
Multi-year collaborations for AI-driven drug discovery programs
Pfizer collaboration announcement
NIH Grant Funding$68M
Funding for AI-powered antiviral drug discovery consortium
NIH partnership announcement
Internal Pipeline DevelopmentN/A - Wholly owned programs
PCOS, reproductive endocrinology, fertility programs

How Does PostEra Compare to Competitors?

FeaturePostEraInsilico MedicineExscientiaRecursion
Core FunctionalityGenerative chemistry & synthesis-aware designGenerative AI for moleculesAI-driven design-make-test-learnPhenomics-based discovery
Pricing (Deal Size)Up to $610M (Pfizer)Up to $3B (Sanofi)Up to $2B (BMS)Custom partnerships
Free Tier Availability
Enterprise FeaturesMilestones + royaltiesMilestones + royaltiesMilestones + royaltiesMilestones + royalties
API AvailabilityProprietary platform (Proton)Chemistry42 platformCentaur ChemistRecursion OS
Integration CountPartners: Pfizer, Amgen, NIHSanofi, Eli LillyBMS, J&JNVIDIA, Roche
Support OptionsDedicated partnership teamsEnterprise supportEnterprise supportEnterprise support
Security CertificationsN/A (pharma standards)
Core Functionality
PostEraGenerative chemistry & synthesis-aware design
Insilico MedicineGenerative AI for molecules
ExscientiaAI-driven design-make-test-learn
RecursionPhenomics-based discovery
Pricing (Deal Size)
PostEraUp to $610M (Pfizer)
Insilico MedicineUp to $3B (Sanofi)
ExscientiaUp to $2B (BMS)
RecursionCustom partnerships
Free Tier Availability
PostEra—
Insilico Medicine—
Exscientia—
Recursion—
Enterprise Features
PostEraMilestones + royalties
Insilico MedicineMilestones + royalties
ExscientiaMilestones + royalties
RecursionMilestones + royalties
API Availability
PostEraProprietary platform (Proton)
Insilico MedicineChemistry42 platform
ExscientiaCentaur Chemist
RecursionRecursion OS
Integration Count
PostEraPartners: Pfizer, Amgen, NIH
Insilico MedicineSanofi, Eli Lilly
ExscientiaBMS, J&J
RecursionNVIDIA, Roche
Support Options
PostEraDedicated partnership teams
Insilico MedicineEnterprise support
ExscientiaEnterprise support
RecursionEnterprise support
Security Certifications
PostEraN/A (pharma standards)
Insilico Medicine—
Exscientia—
Recursion—

How Does PostEra Compare to Competitors?

vs Insilico Medicine

While both companies specialize in generative chemistry with synthesis-aware design via their Proton platform (Postera), whereas Insilico focuses on a broader generative AI approach that can be applied to various modalities. In addition, Postera has strong momentum with its partnership with Pfizer; and Insilico has larger deals such as the Sanofi $3B deal.

PostEra is superior in chemistry optimization; and Insilico is superior in overall end-to-end discovery platforms.

vs Exscientia

Both companies are AI first but Exscientia places greater emphasis on the closed-loop design-make-test-learn cycles and has more clinical assets than PostEra. Additionally, PostEra has stronger upfront payment opportunities and has received NIH funding for its work in antiviral research. Exscientia has a larger market capitalization and more partnerships.

Exscientia is superior for clinical progression; and PostEra is superior for preclinical acceleration.

vs Recursion Pharmaceuticals

Recursion utilizes phenomics/industrialized biology vs the chemistry-based AI of PostEra. Recursion has a huge data scale advantage over PostEra but it also has a significantly higher burn rate. PostEra has more focus on optimizing small molecules and includes synthesis optimization.

Recursion is superior for biology-first discovery; and PostEra is superior for chemistry-led optimization.

vs Absci

Absci has a focus on de novo protein design whereas PostEra has expertise in small molecules. PostEra has stronger big pharma validation (multi-year Pfizer deal) whereas Absci is targeting biologics.

PostEra is superior for small molecules; and Absci is superior for protein therapeutics.

What are the strengths and limitations of PostEra?

Pros

  • Proven big pharma validation — Multiple multi-year Pfizer deals totaling $610M+
  • Synthesis-aware AI design — Proton platform designs for optimal synthesis
  • Immediate payment of $12 million by Pfizer as part of their expansion
  • Credibility through NIH backing — a $68M grant for developing antivirals for pandemic preparedness
  • Control over your internal pipeline development — wholly owned programs in PCOS/Fertility
  • Validated track record of $1 billion + partnership — Amgen, Pfizer, NIH have validated your platform
  • Peer-review validation of faster preclinical milestones — publications validate

Cons

  • Business-to-business (B2B) model only — no SaaS/self-service pricing for individual researcher use
  • Sales cycles are long — requires negotiating an enterprise partnership agreement
  • Therapeutic area is very narrow — primarily focused on small molecule chemistry optimization
  • No public price transparency — custom quote only; difficult to compare/establish benchmarks
  • Pre-revenue — revenue will be tied to future milestones/distant royalty payments
  • High risk associated with partnerships — success is dependent upon partner progress into clinic
  • Limited publicly available case studies — results are typically linked to confidential pharma programs

Who Is PostEra Best For?

Best For

  • Large biopharma companies — Proven with Pfizer (over $610M+ in deals), Amgen — able to handle complex enterprise programs
  • Small molecule discovery teams — The Proton Platform specializes in generative chemistry and synthesis-aware design
  • Pandemic preparedness programs — NIH $68M Consortium validates capabilities in antiviral discovery
  • Companies seeking preclinical acceleration — Peer-review validation of faster milestone achievement versus traditional methods
  • Partners wanting cost/time savings — AI Platform designed to lower early-stage discovery timelines and costs

Not Suitable For

  • Academic researchers or startups — Only enterprise partnership model; consider using open-source alternatives such as RDKit if you do not require a formal partnership agreement
  • Protein/biologics developers — Focus is only on small molecule chemistry; consider Absci or Generate:Biomedicines for protein-based drugs
  • Individual medicinal chemists — No SaaS/self-service pricing; formal partnership agreement required
  • Late-stage clinical companies — Only preclinical focus; partners will be responsible for progressing IND/clinical

Are There Usage Limits or Geographic Restrictions for PostEra?

Target Scope
Small molecule therapeutics and ADC payloads
Partnership Model
B2B co-discovery only, no self-service
Therapeutic Areas
Partner-selected targets + internal PCOS/fertility/antivirals
Pipeline Ownership
Partner decides IND sponsor/clinical rights
Discovery Phase
Preclinical only up to Development Candidate nomination
Accessibility
Enterprise pharma partners only, no public API
Geographic Availability
Global partnerships (US-based company)

Is PostEra Secure and Compliant?

Pharma Industry StandardsWorks with Pfizer, Amgen, NIH meeting enterprise biopharma security requirements.
Confidential IP ProtectionHandles sensitive drug discovery data for Fortune 500 pharma partners.
Data SecurityProprietary Proton platform processes chemical structures securely.
Government ComplianceNIH-funded programs meet federal research security standards.
Partnership NDAsStandard biopharma collaboration agreements with IP protections.

What Customer Support Options Does PostEra Offer?

Channels
Assigned for each biopharma collaborationJoint research teams with Pfizer, Amgen scientistsCEO/CSO level engagement for major programs
Hours
As required for multi-year partnerships
Response Time
Dedicated resources for enterprise partners
Satisfaction
Validated by repeat Pfizer deals ($610M+ total)
Specialized
Domain experts in generative chemistry and synthesis
Business Tier
Custom support for each Fortune 500 partner

What APIs and Integrations Does PostEra Support?

API Type
No public API available. PostEra operates as an enterprise AI platform for biopharma partners with no developer-facing API integrations found.
Authentication
Not applicable - no public API or developer portal identified.
Webhooks
Not supported - no webhook capabilities mentioned in public documentation.
SDKs
None available publicly. No GitHub repositories or official SDKs for external developers.
Documentation
No API documentation available. Website focuses on enterprise partnerships rather than self-serve API access.
Sandbox
Not available - platform designed for partnered drug discovery programs.
SLA
Enterprise partnership agreements only - no public SLA details.
Rate Limits
Not applicable - no public API.
Use Cases
Enterprise medicinal chemistry acceleration through direct partnerships with pharma companies like Pfizer and Amgen.

What Are Common Questions About PostEra?

Proton is the end-to-end machine learning platform for medicinal chemistry developed by PostEra that enables closing the Design-Make-Test cycle. Using AI foundation models to generate synthesizable molecules, Proton predicts properties and selects the best compounds for testing. Thus, it accelerates small molecule drug discovery for both internal pipeline and pharma partnerships.

Pharma/Biotech partners determine the biological targets, and develop assays. PostEra will use Proton to identify and optimize a small molecule candidate as a Development Candidate nominee. After that point, the partner determines what IND enabling studies are needed and how to take the program into the clinic. In exchange, PostEra will receive an upfront payment, milestone payments, and royalty payments on all successful programs.

PostEra has wholly owned programs in PCOS, reproductive endocrinology, and fertility. Additionally, PostEra has 4 partnered preclinical programs across multiple therapeutic areas with associated milestones and rights to economics. The primary goal of PostEra is to accelerate its own cures by utilizing its Proton platform.

PostEra has collaborated with Pfizer (the collaboration was expanded to $610M total value and includes ADCs) , Amgen (as many as 5 programs) and NIH (PostEra received the largest grant from NIH for the antiviral center). PostEra has closed over $1B in AI partnership agreements which demonstrates significant industry validation.

PostEra specializes in generating chemical compounds in accordance with synthetic requirements across the entire design-make-test cycle through proprietary data and foundation models. As opposed to target identification focused competitors, PostEra optimizes medicinal chemistry for real world synthesizability and parallel manufacture.

Yes, through peer reviewed publications with Pfizer illustrating that Preclinical Milestones were achieved faster than previous methods; through the success of the Open Science COVID MoonShot project; and through the expansion of the partnerships with industry leading pharmaceutical companies. There are numerous programs that have successfully progressed through the partnered discovery phase.

The focus of PostEra’s internal pipeline is women’s health (PCOS, fertility, reproductive endocrinology). PostEra’s partnered programs include 4 preclinical programs across 2 undisclosed therapeutic areas and ADC payload programs with Pfizer and Amgen.

PostEra provides large pharma partners with customized collaborative services. There is no self-service platform, free trial, or public pricing options available for smaller organizations. Revised text for a more human-like tone: BEGIN_TEXT

Is PostEra Worth It?

PostEra has made a strong case for its state-of-the-art AI applications in medicinal chemistry through large pharmaceutical partnerships that total more than $1B. PostEra’s Proton Platform is differentiated by both the synthesis-aware design, as well as the fully integrated Design-Make-Test cycle for competitive advantage. Although they have proven their ability to operate at an enterprise level, the company limits accessibility to those who are partners with them strategically.

Recommended For

  • Pharmaceutical companies looking for ways to accelerate medicinal chemistry using AI
  • Biotech companies that have clearly identified targets looking for small molecules synthesized to optimize their target(s).
  • Companies looking for validated AI platforms that have a history of partnering with pharmaceuticals.
  • Companies that prioritize the efficiency of their preclinical drug discovery cycle.

!
Use With Caution

  • Smaller biotechs or academic labs – the partnership model typically requires a significant commitment from the organization.
  • Companies looking for target identification (PostEra is focused on optimizing the chemistry after target selection).
  • Organizations that require self-service platforms or rapid prototyping.

Not Recommended For

  • Individual researchers or hobbyists – the company’s model is for enterprise only.
  • Discovery teams focused on biology-first approaches – the team specializes in chemistry after they select the target.
  • Organizations with budget constraints - the company offers custom partnership economics only.
Expert's Conclusion

PostEra is best suited for pharmaceutical companies that want to accelerate medicinal chemistry through proven AI partnerships; however, the company will require an enterprise-level commitment.

Best For
Pharmaceutical companies looking for ways to accelerate medicinal chemistry using AIBiotech companies that have clearly identified targets looking for small molecules synthesized to optimize their target(s).Companies looking for validated AI platforms that have a history of partnering with pharmaceuticals.

What do expert reviews and research say about PostEra?

Key Findings

PostEra specializes in AI-powered medicinal chemistry through the Proton Platform, which uses synthesis-aware Design-Make-Test cycles. The company has validated this approach through $1B+ partnerships with Pfizer ($610M expanded), Amgen, and NIH. Additionally, the company has an internal pipeline in women’s health and four partnered preclinical programs. Some competitors to PostEra include Exscientia and Insilico Medicine; however, PostEra differentiates itself through the optimization of chemistry based on manufacturing.

Data Quality

Good - comprehensive information from official website, press releases, and partner announcements. No public pricing, API docs, or self-serve platform details as enterprise partnership model.

Risk Factors

!
Limited accessibility due to the enterprise-only access model prevents PostEra from being evaluated against a wider range of markets.
!
Focus on chemistry post-target ID vs. focus on end-to-end discovery.
!
Dependency on partnerships to validate clinical use.
!
Competitive landscape for AI-based drug discovery
Last updated: February 2026

What Additional Information Is Available for PostEra?

Major Partnerships

The following information about Exscientia was obtained by searching the internet using the company name as a search term:

Leadership Team

Exscientia is an AI-powered drug discovery engine that has entered into a number of collaborations in order to apply its technology to drug development. Some of the most recent collaborations include: Pfizer: A collaboration worth over $610 million that includes developing new drugs and antibody-drug conjugates as part of the collaboration. This collaboration was extended beyond the original agreement to continue to develop new compounds through the application of the AI technology. The results of this collaboration were published in a peer reviewed journal where the authors demonstrated that the use of AI allowed them to meet their milestones more quickly than they would have been able to otherwise. Amgen: Five different programs were initiated under a collaboration between Exscientia and Amgen to utilize the AI technology developed by Exscientia to develop new drugs. NIH: Exscientia received the largest grant ever given by the National Institutes of Health for the purpose of utilizing the AI technology developed by the company to develop new antiviral compounds.

COVID Moonshot

The team at Exscientia consists of: Aaron Morris, CEO Alpha Lee, CSO Matthew Robinson, CTO Tony Schroeder, Head of Machine Learning Emily Hanan, Head of Medicinal Chemistry The team at Exscientia combines both deep machine learning and medicinal chemistry experience to develop new compounds.

Pipeline Progress

The team at Exscientia has utilized the AI technology developed by the company to lead the world's largest open-source drug discovery effort for the purpose of developing new antiviral compounds. In addition to developing new compounds, the AI technology has also been used to unite researchers from around the globe to help accelerate the development of new COVID-19 treatments.

Technology Integration

Exscientia has wholly-owned preclinical development programs in the treatment of polycystic ovary syndrome, fertility, and other disorders of the reproductive endocrine system. In addition to these wholly-owned programs, Exscientia has four partnered preclinical development programs with established pharmaceutical companies. These programs are progressing toward achieving the next milestone, which will be IND-enabling studies.

What Are the Best Alternatives to PostEra?

  • •
    Exscientia: Exscientia has worked with Optibrium to integrate their StarDrop de novo design tool into Exscientia's drug discovery process. The integration with Optibrium's software allows Exscientia to use the software to perform de novo design to generate new molecules that can then be evaluated using Exscientia's AI technology to determine if the molecules are viable candidates to be progressed through the drug development process. In addition to integrating Optibrium's software, Exscientia has also worked with PostEra to integrate their Manifold retrosynthesis tool into the drug discovery process. The integration with PostEra's software allows Exscientia to perform retrosynthesis to generate new molecules from existing synthetic intermediates. The ability to perform both de novo design and retrosynthesis allows Exscientia to evaluate a wide variety of potential drug candidates simultaneously, while also reducing the amount of time and resources needed to identify a candidate compound. Furthermore, because the two tools operate in parallel, Exscientia is able to evaluate the same synthetic intermediates for both de novo design and retrosynthesis, allowing the company to efficiently utilize its resources.
  • •
    Insilico Medicine: Exscientia has developed a number of clinical assets that it has discovered using its AI technology. Exscientia has also partnered with several pharmaceutical companies to further develop the clinical assets. However, the majority of the clinical assets developed by Exscientia are being developed in-house. Because Exscientia develops many of its clinical assets internally, the company is able to maintain full control over the development of its assets, allowing Exscientia to make decisions regarding the development of its assets based on what is best for the company. Additionally, because Exscientia develops its clinical assets internally, the company is able to move its assets forward in the drug development process much more quickly than it would have been able to if it had relied on partnering with other companies.
  • •
    Atomwise: Compared to PostEra, Exscientia is a more comprehensive drug discovery platform. Unlike PostEra, which focuses primarily on performing chemistry optimization, Exscientia performs end-to-end drug discovery, which means that Exscientia can take a lead compound from the initial stages of drug discovery all the way through to the clinic. Additionally, compared to PostEra, Exscientia has established partnerships with several large pharmaceutical companies, which provides Exscientia with access to additional funding and resources. Because of its comprehensive nature and access to funding and resources, Exscientia is better suited to companies looking to implement a complete drug discovery platform.
  • •
    BenevolentAI: Insilico Medicine is a company that utilizes AI to discover new medicines. The company uses a form of AI called generative AI to identify potential drug targets and to design potential drugs. Insilico Medicine is focused on earlier-stage discovery, whereas Exscientia is focused on later-stage discovery, specifically optimizing chemistry to select the best candidates for progression to the clinic. As such, Insilico Medicine is best suited for companies that are looking to explore novel targets in various therapeutic areas, while Exscientia is best suited for companies that are looking to optimize chemistry to select the best candidates for progression to the clinic.
  • •
    Recursion Pharmaceuticals: The use of AI and large-scale cellular imaging for identifying phenotypes that lead to drug discovery. AI will be used to identify how a compound interacts with cells, while PostEra will provide a range of small molecules to test. The company has several pipeline projects and clinical-stage candidates, and is best suited for identifying new mechanisms of action using an unbiased approach to cell function. (Recursion.com)

Scientific ROI Metrics

Faster than anticipated
Preclinical Milestone Acceleration
Over $1B USD
Drug Discovery Partnerships Value
$610M USD
Pfizer Collaboration Expansion
4+ preclinical programs
Internal Pipeline Programs
Accelerated via AI
Design-Make-Test Cycle Speed

Core Discovery Capabilities

Design-Make-Test Cycle Closure

An end-to-end machine learning platform called Proton for continuous medicinal chemistry from design through to synthesis and testing.

Generative Chemistry

Synthesis-aware molecule design to ensure that all chemical compounds have reliable synthetic routes and can be made in parallel.

Active Learning

New methods to determine which of the many possible molecules should be tested at each iteration of the process.

Structure-Enabled & Non-Structural AI

Simulate interactions of target molecules with proteins, whether or not there is structural information available.

Payload Optimization for ADCs

Use AI to optimize properties of antibody-drug conjugates (ADCs).

Retrosynthesis Planning

Manifold software for predicting synthetic routes to molecules using machine learning.

Medicinal Chemistry Prioritization

Combine parallel chemistry with AI to guide the order of molecular modifications that should be prioritized.

ML Architecture & Computational Specifications

Core Platform
Proton - End-to-end ML for medicinal chemistry Design-Make-Test
Key Components
Chemistry foundation models, generative chemistry, synthesis-aware design
Retrosynthesis Tool
Manifold - ML algorithms for synthetic route prediction
Model Interpretability
Non-black box approach with validated predictions
Data Handling
Proprietary data integration with active learning for noisy/small datasets
Target Engagement
Structure-based interaction simulation + structure-agnostic tools
Validation Approach
Peer-reviewed publications with pharma partners (Pfizer)
Deployment Model
AI-first platform with biopharma co-discovery partnerships
Partnership Integration
Pfizer AI Lab, Amgen multi-target, Optibrium StarDrop
Focus Areas
Small molecules, ADC payloads, preclinical optimization

What Primary Use Cases Does PostEra Offer?

Medicinal Chemistry Design-Make-Test AccelerationSynthesis-Aware Generative ChemistryActive Learning for Optimal Molecule SelectionPreclinical Small Molecule DiscoveryADC Payload OptimizationStructure-Enabled Target EngagementCOVID Antiviral Design (Pandemic Response)Pfizer AI Lab Multi-Target CampaignsAmgen 5-Target Small Molecule ProgramsInternal PCOS/Fertility Pipeline

What Is PostEra's Regulatory Compliance Requirements Status?

Pharma Partnership ValidationMulti-year collaborations with Pfizer ($610M), Amgen
Peer-Reviewed Model ValidationPublications validating AI impact on preclinical milestones
Preclinical Pipeline Advancement4+ wholly-owned programs in reproductive endocrinology
IND-Enabling Studies ReadinessCo-discovery model advances candidates to IND
Proprietary Data ProtectionPlatform handles partner proprietary datasets securely
Model Uncertainty QuantificationTrained models that 'know what they don't know'
Reproducibility & InterpretabilityNon-black box technology validated in real programs
NIH Grant ComplianceLargest NIH grant for antiviral center operations
FDA Submission SupportPreclinical focus; clinical partnerships determine path
IP Protection in PartnershipsMilestones and royalties structure preserves IP

Integration & Workflow Capabilities

Biopharma Target Selection Workflow

Partners define their target, assay, and technology platform and postera leads the research through development candidate nomination.

Pfizer AI Lab Integration

Close multi-year partnerships are being advanced to move forward on small molecule programs.

Amgen Multi-Target Collaboration

Through use of the Proton platform, progress has been made toward developing five small molecule programs.

Optibrium StarDrop Integration

Combination of Manifold retrosynthesis and de novo design tools.

Parallel Medicinal Chemistry

Enable the use of AI to prioritize the synthesis of common intermediates.

Active Learning Loops

Optimal experimental design-make-test cycles.

Structure & Assay Cascade Integration

Partner biology expertise is combined with computational chemistry to advance the partnership.

ADC Payload Design Workflow

Optimization of payload for antibody-drug conjugates.

Pandemic Response Scalability

Rapid design of antivirals was validated during Recursion’s COVID-19 program.

Co-Discovery Partnership Model

Flexible IND/clinical sponsorships agreements.

AI Drug Discovery Platform Performance Benchmarks

Performance MetricPostEra ProtonTraditional MethodImprovement Factor
Design-Make-Test CyclesAI-accelerated iterative cyclesManual medicinal chemistrySignificantly faster
Preclinical Milestone AchievementFaster than anticipated (Pfizer)Standard timelinesValidated acceleration
Partnership Investment Secured$1B+ (Pfizer, Amgen, NIH)Proven commercial validation
Pipeline Advancement4+ preclinical wholly-owned + partneredTraditional discovery attritionMultiple programs progressed
Synthesis Route PredictionML-powered ManifoldExpert retrosynthesisParallel chemistry enabled
Pandemic Response SpeedRapid COVID antivirals from codeMonths of manual designDramatically accelerated
Model ValidationPeer-reviewed pharma partnershipsInternal benchmarks onlyReal-world proven
InterpretabilityNon-black box validatedOpaque deep learningChemist-trusted predictions

AI Drug Discovery Platform Evaluation Priority Matrix

Priority LevelEvaluation CategoryKey Assessment Questions
1 - CRITICALPharma Partnership ValidationMulti-year collaborations with Pfizer ($610M), Amgen demonstrating real program success?
1 - CRITICALPreclinical Milestone EvidenceDocumented acceleration beyond anticipated timelines in peer-reviewed publications?
2 - HIGHEnd-to-End Medicinal ChemistryTrue Design-Make-Test closure with synthesis-aware generative design and active learning?
2 - HIGHInterpretability & TrustNon-black box models validated by top chemists that 'know what they don't know'?
3 - MEDIUMPartnership & Integration MaturityProven co-discovery model with flexible IND/clinical handoff and tool integrations?
3 - MEDIUMTherapeutic Area BreadthSuccess across antivirals, ADCs, reproductive endocrinology, small molecules?
4 - MEDIUMScalability & Platform DepthManifold retrosynthesis, Proton platform handling structure-aware/non-aware targets?
5 - LOWERInternal Pipeline ProgressWholly-owned programs reaching preclinical milestones independently?

Expert Reviews

📝

No reviews yet

Be the first to review PostEra!

Write a Review

Similar Products

BenevolentAI
benevolent.ai
Recursion Pharmaceuticals
recursion.com
Valar Labs
valarlabs.com